Abstract
The mammalian target of rapamycin (mTOR) is a PI3K-related serine/threonine kinase and plays a critical role in modulating proliferation, growth, survival, invasion and chemoresistance of multiple myeloma, a malignancy of plasma cells. Since it was identified as the therapeutic target of rapamycin, mTOR has been applied for anti-cancer drug discovery. More and more mTOR inhibitors have been developed and demonstrated with great clinical potentials for multiple myeloma and other cancers. In this review, we highlighted advances in drug discovery targeting the mTOR signaling pathway for the treatment of multiple myeloma with an input from our recent studies.
Keywords: Mammalian target of rapamycin (mTOR), mTOR complex 1, mTOR complex 2, multiple myeloma, drug discovery.
Current Pharmaceutical Design
Title:The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Volume: 20 Issue: 1
Author(s): Jie Li, Jingyu Zhu, Biyin Cao and Xinliang Mao
Affiliation:
Keywords: Mammalian target of rapamycin (mTOR), mTOR complex 1, mTOR complex 2, multiple myeloma, drug discovery.
Abstract: The mammalian target of rapamycin (mTOR) is a PI3K-related serine/threonine kinase and plays a critical role in modulating proliferation, growth, survival, invasion and chemoresistance of multiple myeloma, a malignancy of plasma cells. Since it was identified as the therapeutic target of rapamycin, mTOR has been applied for anti-cancer drug discovery. More and more mTOR inhibitors have been developed and demonstrated with great clinical potentials for multiple myeloma and other cancers. In this review, we highlighted advances in drug discovery targeting the mTOR signaling pathway for the treatment of multiple myeloma with an input from our recent studies.
Export Options
About this article
Cite this article as:
Li Jie, Zhu Jingyu, Cao Biyin and Mao Xinliang, The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma, Current Pharmaceutical Design 2014; 20 (1) . https://dx.doi.org/10.2174/13816128113199990638
DOI https://dx.doi.org/10.2174/13816128113199990638 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
Current Pharmaceutical Design Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy CD248: Reviewing its Role in Health and Disease
Current Drug Targets A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design The Indolylcoumarin COUFIN Exhibits Potent Activity Against Renal Carcinoma Cells without Affecting Hematopoietic System
Anti-Cancer Agents in Medicinal Chemistry Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells
Current Pharmaceutical Design Network Pharmacology-based Prediction and Verification of Shikonin for Treating Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Anti-Tumour Effects of Bisphosphonates - What have we Learned from In Vivo Models?
Current Cancer Drug Targets A Comprehensive Review on Pharmacology and Toxicology of Bioactive Compounds of <i>Lagerstroemia Speciosa(L.</i>) Pers.
Current Traditional Medicine microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property
Anti-Cancer Agents in Medicinal Chemistry Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Current Drug Targets Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets